Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II of Single Agent Cabozantinib in Patients With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma Post Immunotherapy or Who Are Unsuitable for Immunotherapy (ANZUP1802)

NCT03685448 is registered in ClinicalTrials.gov with Australian and New Zealand Urogenital and Prostate Cancer Trials Group as lead sponsor.

NCT NCT03685448
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03685448 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II of Single Agent Cabozantinib in Patients With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma Post Immunotherapy or Who Are Unsuitable for Immunotherapy (ANZUP1802)
Lead sponsor
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase
Phase 2
Overall status
Completed
Start date
April 11, 2019
Completion date
June 4, 2025
Enrollment
35 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

chromophobe renal cell carcinoma, papillary renal cell carcinoma type 1, papillary renal cell carcinoma type 2, renal cell carcinoma, sarcomatoid renal cell carcinoma, xp11.2 translocation-related renal cell carcinoma